Publicaciones en las que colabora con María Sanjurjo Sáez (17)

2024

  1. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors

    European Journal of Hospital Pharmacy, Vol. 31, Núm. 5, pp. 409-415

2020

  1. Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients with Cancer on Their Health Outcomes: Quasi-Experimental Study

    JMIR mHealth and uHealth, Vol. 8, Núm. 10

  2. Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents

    American Journal of Health-System Pharmacy, Vol. 77, Núm. 17, pp. 1393-1402

  3. Risks and medication errors analysis to evaluate the impact of a chemotherapy compounding workflow management system on cancer patients’ safety

    Health Informatics Journal, Vol. 26, Núm. 3, pp. 1995-2010

2019

  1. Development and Evaluation of a Clinical Decision Support System to Improve Medication Safety

    Applied Clinical Informatics, Vol. 10, Núm. 3, pp. 513-520

  2. Drug cost avoidance in clinical trials of breast cancer

    Journal of Oncology Pharmacy Practice, Vol. 25, Núm. 5, pp. 1099-1104

  3. Robotic dispensing improves patient safety, inventory management, and staff satisfaction in an outpatient hospital pharmacy

    Journal of Evaluation in Clinical Practice, Vol. 25, Núm. 1, pp. 28-35

2018

  1. Drug cost avoidance resulting from breast cancer clinical trials

    European Journal of Clinical Pharmacy, Vol. 20, Núm. 1, pp. 6-10

  2. Estudio comparativo de contaminación de tres sistemas cerrados para la preparación de fármacos peligrosos mediante simulación con fluoresceína

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 42, Núm. 6, pp. 234-238

  3. Failure mode and effects analysis to improve quality in clinical trials

    Journal of Healthcare Quality Research, Vol. 33, Núm. 1, pp. 33-47

  4. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

    Expert Opinion on Drug Safety, Vol. 17, Núm. 3, pp. 235-241

2016

  1. Guiding pharmacist clinical interviews: A safety tool to support the education of patients treated with oral antineoplastic agents

    Expert Opinion on Drug Safety, Vol. 15, Núm. 4, pp. 427-435

  2. Optimisation of antithrombotic therapy in patients with acute coronary syndrome to reduce bleeding episodes

    International Journal of Clinical Practice, Vol. 70, Núm. 2, pp. 156-162

  3. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account

    Journal of Cancer Research and Clinical Oncology, Vol. 142, Núm. 11, pp. 2319-2330

  4. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction

    International Journal of Clinical Pharmacy, Vol. 38, Núm. 2, pp. 280-288

2014

  1. Implementing smart pump technology in a pediatric intensive care unit: A cost-effective approach

    International Journal of Medical Informatics, Vol. 83, Núm. 2, pp. 99-105

2013

  1. Impact of implementing smart infusion pumps in a pediatric intensive care unit

    American Journal of Health-System Pharmacy, Vol. 70, Núm. 21, pp. 1897-1906